News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Tiziana Life Sciences Ltd director Gabriele M. Cerrone, through Panetta Partners Limited, purchased 15,000 shares of common stock at $1.11 per share on June 12, 2026, bringing indirect holdings to 44,772,230 shares. This Form 4/A amendment primarily updates the transaction code for this open-market …
Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi recently increased his stake in the company by purchasing 321,423 common shares at $1.00 each on Nasdaq, bringing his total holdings to 4,793,684 common shares. The company is actively developing intranasal foralumab, a fully human anti-CD3 monoclonal …
Tiziana Life Sciences CEO Ivor Elrifi recently purchased 237,616 shares of the company's stock at $1.00 per share, increasing his direct ownership to 4.79 million shares. This latest acquisition follows earlier purchases of 83,807 shares and 667,000 shares in the same week. Despite the …
Tiziana Life Sciences CEO Ivor Elrifi has increased his stake in the company by purchasing 321,423 common shares at $1.00 per share, bringing his total holdings to 4,793,684 shares. The company highlighted its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, …
Tiziana Life Sciences CEO Ivor Elrifi increased his stake in the company by purchasing 667,000 common shares, signaling strong insider confidence. This move coincides with the promising progress of their lead drug, intranasal foralumab, for non-active secondary progressive multiple sclerosis, which has shown positive …
Tiziana Life Sciences Ltd's CEO, Ivor Elrifi, purchased 667,000 shares of common stock through a trust on August 3, 2026, at $1.00 per share. This transaction, classified as an open-market or private purchase, increased his indirect holdings by trust to 4,472,261 shares. The company …
Tiziana Life Sciences Ltd. (NASDAQ:TLSA) CEO Ivor Elrifi has increased his stake in the company by purchasing 667,000 common shares at US$1 per share on Nasdaq, bringing his total holdings to 4,472,261 shares. Tiziana is focused on developing immunomodulation therapies, particularly intranasal foralumab, a …
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and neuroinflammatory diseases. The company's stock closed at $0.959 on August 3, 2026, experiencing a 6.86% decrease. Analysts currently rate TLSA as a "Buy" with a target price …
This article provides a financial overview of Tiziana Life Sciences Ltd (NASDAQ: TLSA) on TradingView. It indicates that the market was closed at the time of viewing and offers access to various financial data, including statements, statistics, dividends, earnings, and segment performance. Users can …
This small cap wrap highlights several companies' recent developments. Medicus Pharma received IND authorization for its Phase 2a endometriosis clinical study in the UAE, while Tiziana Life Sciences reported reduced brain inflammation in an MSA patient treated with intranasal foralumab. Namibia Critical Metals announced …
Tiziana Life Sciences announced positive results from the third patient in its Phase 2 clinical trial for intranasal foralumab in Multiple System Atrophy (MSA). The patient showed a significant 34% reduction in neuroinflammatory activity in affected brain regions, consistent with previous patients. This suggests …
Tiziana Life Sciences (Nasdaq: TLSA) announced positive PET imaging data from a third patient in its Phase 2 trial for intranasal foralumab in Multiple System Atrophy (MSA), showing up to 34% reduction in SUV and 26% reduction in SUVR, consistent with previous patients. These …
This article provides a financial analysis of Tiziana Life Sciences Ltd (TLSA), focusing on its profitability and balance sheet. It notes the current stock price and market capitalization, indicating a negative performance on the closing day. The content serves as a general information piece …
This article provides a technical analysis of Tiziana Life Sciences Ltd (TLSA) stock, covering key indicators like MACD, RSI, and moving averages. It summarizes both indicator values and their directional signals, revealing a mixed outlook with some buy and sell signals. The analysis aims …
This article provides a detailed cash flow statement for Tiziana Life Sciences Ltd (TLSA), covering quarterly and annual data up to FY2024H2. It breaks down operating, investing, and financing cash flows, along with related metrics like net income, capital expenditures, and free cash flow. …
Tiziana Life Sciences Ltd. is a UK-based clinical-stage biotechnology company focused on neurodegenerative and neuroinflammatory diseases, including secondary progressive multiple sclerosis, Alzheimer's, and ALS. Their pipeline features Foralumab (TZLS-401) and Anti-IL-6R mAb (TZLS-501), alongside oncology candidate Milciclib for refractory solid tumors. The company's stock, …
This page provides the quarterly income statement for Tiziana Life Sciences Ltd (TLSA), offering detailed financial data such as total revenue, operating expenses, research and development expenses, operating profit, and net income for various fiscal periods. It also includes frequently asked questions about interpreting …
This article provides a revenue breakdown for Tiziana Life Sciences Ltd. (FWB:0RP) on TradingView. It appears to be a stub or an incomplete financial overview, focusing on the lack of specific revenue data with placeholders for segments and regional performance. The content primarily lists …
Tiziana Life Sciences Ltd (TLSA) director Gabriele M. Cerrone was awarded 42,357 shares of common stock at $0.99 per share on July 21, 2026, through indirect ownership via Panetta Partners Limited. Following this transaction, Cerrone's associated holdings total 44,814,587 common shares. This information was …
Tiziana Life Sciences' executive chairman and founder, Gabriele Cerrone, has increased his stake in the company by purchasing 42,357 common shares at $0.99 each through Panetta Partners. This acquisition brings his total holdings to 44.8 million common shares, representing 34.93% of the company's issued …
Tiziana Life Sciences announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, purchased an additional 42,357 common shares at $0.99 per share. This brings his total holding to 44,814,587 common shares, representing 34.93% of the company's issued share capital. …
Tiziana Life Sciences' Executive Chairman and Founder, Gabriele Cerrone, has increased his stake in the company to 34.93% by purchasing an additional 42,357 common shares at $0.99 each through Panetta Partners Ltd. This transaction brings his total holding to 44,814,587 shares. The company is …
Search by ticker symbol or company name and select a result to open its chart.